Correction: Ruxolitinib sensitizes ovarian cancer to reduced dose Taxol, limits tumor growth and improves survival in immune competent mice

Patrick M. Reeves; Mojgan A. Abbaslou; Farah R.W. Kools; Kritchai Vutipongsatorn; Xiaoyun Tong; Christina Gavegnano; Raymond F. Schinazi; Mark C. Poznansky

doi:10.18632/oncotarget.25791

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: Ruxolitinib sensitizes ovarian cancer to reduced dose Taxol, limits tumor growth and improves survival in immune competent mice

PDF | How to cite

Oncotarget. 2018; 9:30472-30472. https://doi.org/10.18632/oncotarget.25791

Metrics: PDF 1666 views | ?

Patrick M. Reeves¹, Mojgan A. Abbaslou¹, Farah R.W. Kools¹, Kritchai Vutipongsatorn¹, Xiaoyun Tong¹, Christina Gavegnano², Raymond F. Schinazi² and Mark C. Poznansky¹

¹ Vaccine and Immunotherapy Center, Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, MA 02129, USA
² Center for AIDS Research, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA

Published: July 13, 2018

This article has been corrected: The correctly spelled author name is given below:

Christina Gavegnano

Original article: Oncotarget. 2017; 8:94040-94053. DOI: https://doi.org/10.18632/oncotarget.21541.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 25791

Publication Alerts

Post-Publication Promotion

Publication Discount

Corrections:

Correction: Ruxolitinib sensitizes ovarian cancer to reduced dose Taxol, limits tumor growth and improves survival in immune competent mice